🔍 Definition
Parkinson’s disease (PD) is a chronic, progressive neurodegenerative disorder characterized by the selective loss of dopaminergic neurons in the substantia nigra pars compacta and the accumulation of misfolded alpha-synuclein protein aggregates (Lewy bodies) in surviving neurons. The pathological hallmark is dopamine depletion in the nigrostriatal pathway, producing the cardinal motor features of the disease. According to the Parkinson’s Foundation, approximately 1 million people in the United States currently live with Parkinson’s disease, with nearly 90,000 new diagnoses each year.
For coding purposes, a critical distinction exists among three categories:
- Idiopathic (primary) Parkinson’s disease — coded to category G20.x. This is the most common form, representing approximately 85–90% of all parkinsonism cases, and arises from unknown etiology with characteristic Lewy body pathology.
- Secondary parkinsonism — coded to category G21.x. These are parkinsonian syndromes caused by identifiable external factors including drugs, toxins, vascular disease, or infection.
- Parkinson-plus syndromes (degenerative basal ganglia diseases) — coded to category G23.x. These atypical parkinsonisms include progressive supranuclear palsy (PSP), multiple system atrophy (MSA), and others. They differ clinically and have different RAF/HCC implications.
The terms “Parkinson’s disease,” “parkinsonism,” and “Parkinson’s syndrome” are not interchangeable for coding purposes. Effective April 1, 2026, the ICD-10-CM Alphabetic Index was updated so that documented “Parkinson’s disease” directs coders to G20.A1 (not G20.C as before the October 2023 expansion). “Parkinson’s syndrome or tremor” continues to route to G21 (parkinsonism). Verify precise provider language before code assignment.
🗂️ Alternative Terminology
| Formal / Clinical Name | Colloquial / Lay Terms / Synonyms |
|---|---|
| Parkinson’s disease (idiopathic) | Parkinson’s, PD, shaking palsy, paralysis agitans |
| Primary parkinsonism | Idiopathic Parkinson’s, true Parkinson’s |
| Secondary parkinsonism | Drug-induced parkinsonism, vascular parkinsonism, toxic parkinsonism |
| Drug-induced parkinsonism | Neuroleptic-induced parkinsonism, medication-induced parkinsonism |
| Progressive supranuclear palsy (PSP) | Steele-Richardson-Olszewski syndrome |
| Multiple system atrophy (MSA) | Shy-Drager syndrome (historical), MSA-P (parkinsonian variant), MSA-C (cerebellar variant), olivopontocerebellar atrophy |
| Parkinson’s disease with dementia (PDD) | Parkinsonian dementia, dementia in Parkinson’s |
| Dementia with Lewy bodies (DLB) | Lewy body dementia, diffuse Lewy body disease |
| Wearing-off phenomenon | End-of-dose deterioration, “off” episodes, motor fluctuations |
| Levodopa-induced dyskinesia (LID) | Peak-dose dyskinesia, choreiform movements in PD |
| Hoehn and Yahr staging | H&Y scale, PD staging scale |
| Deep brain stimulation (DBS) | Brain pacemaker, DBS implant, neurostimulator therapy |
🩺 Signs & Symptoms
Cardinal Motor Features (TRAP Mnemonic)
- Tremor — Resting tremor (pill-rolling), 4–6 Hz frequency; asymmetric onset; suppressed by voluntary movement
- Rigidity — Cogwheel or lead-pipe resistance to passive movement; may present as shoulder pain
- Akinesia/Bradykinesia — Slowness of initiation and execution of movement; micrographia; hypomimia (masked face); hypophonia
- Postural instability — Impaired balance and righting reflexes; hallmark of later disease (Hoehn-Yahr stage 3+)
Motor Complications (Critical for FY2027 Code Selection)
- Motor fluctuations (“off” episodes) — Wearing-off at end of dose, unpredictable “on/off” switching, early morning akinesia; affects code selection for G20.A2 vs. G20.B2
- Levodopa-induced dyskinesia (LID) — Involuntary choreiform or dystonic movements during “on” periods; key clinical indicator for G20.B1/G20.B2 assignment
- Freezing of gait (FOG) — Sudden inability to initiate or continue walking; major fall risk
Non-Motor Features
- Autonomic dysfunction: Orthostatic hypotension, constipation (K59.00), urinary dysfunction including urinary incontinence (N39.41), sialorrhea, seborrhea
- Cognitive/neuropsychiatric: Mild cognitive impairment, Parkinson’s disease dementia (PDD) — coded with F02.x as manifestation; depression (F32.x/F33.x); anxiety; psychosis (hallucinations, delusions)
- Sleep disorders: REM sleep behavior disorder (RBD) — G47.52 (may precede motor onset by years); insomnia; excessive daytime sleepiness
- Sensory: Anosmia (often pre-motor symptom), pain, restless legs
- Dysphagia: R13.1x — aspiration risk; associated with aspiration pneumonia (J69.0), a major comorbidity requiring attention during inpatient stays
- Falls: W19.xxxA — high frequency, high injury risk; critical to document fall history and Hoehn-Yahr stage
Hoehn and Yahr Staging System
| Stage | Clinical Description | Functional Impact |
|---|---|---|
| Stage 1 | Unilateral disease only; minimal or no functional impairment | Independent |
| Stage 1.5 | Unilateral + axial involvement | Minimal limitation |
| Stage 2 | Bilateral disease, no postural instability | Some limitations, fully independent |
| Stage 2.5 | Bilateral disease, recovery from pull test | Functional with some difficulties |
| Stage 3 | Mild to moderate bilateral disease; postural instability; physically independent | Significant gait/balance issues |
| Stage 4 | Severe disability; still walks, severely limited | Requires assistance; cannot live alone |
| Stage 5 | Wheelchair-bound or bedridden; requires constant care | Total dependence |
Hoehn-Yahr stage is not directly encoded in ICD-10-CM. However, stage documentation drives important code selection decisions: stages 3–5 imply postural instability/gait difficulty (PIGD) variant, which may support W19 fall coding and influence UPDRS documentation, DBS candidacy, and CDI query triggers. Always document the scale score in queries and flag it in the record.
🧭 Differential Diagnosis
| Condition | Key Distinguishing Features | ICD-10-CM Code |
|---|---|---|
| Idiopathic Parkinson’s disease (G20.-) | Asymmetric onset, resting tremor, levodopa responsiveness, Lewy body pathology, gradual progression | G20.A1–G20.B2 (see FY2027 codes below) |
| Drug-induced parkinsonism (G21.11, G21.19) | Symmetric, history of antipsychotic/metoclopramide use, resolves after drug cessation, lacks resting tremor typically | G21.11 (neuroleptic), G21.19 (other) |
| Progressive supranuclear palsy (PSP) (G23.1) | Vertical gaze palsy, falls backward, axial rigidity, early postural instability, poor levodopa response | G23.1 |
| Multiple system atrophy (MSA) / striatonigral degeneration | Autonomic failure (orthostatic hypotension), cerebellar signs, parkinsonian features, poor levodopa response | G90.3 for multi-system degeneration of the autonomic nervous system; G23.2 when documented as striatonigral degeneration; do not use G23.3 for MSA-P/MSA-C in ICD-10-CM |
| Dementia with Lewy bodies (DLB) (G31.83) | Visual hallucinations precede motor features; cognitive fluctuations; REM sleep behavior disorder; sensitivity to antipsychotics; dementia onset within 1 year of motor symptoms | G31.83 |
| Vascular parkinsonism (G21.4) | Lower body predominant (“lower-half parkinsonism”), history of cerebrovascular disease, step-wise progression, white matter lesions on MRI | G21.4 |
| Essential tremor (G25.0) | Action/postural tremor (not resting), family history common, head tremor, voice tremor, no bradykinesia or rigidity, alcohol-responsive | G25.0 |
| Corticobasal syndrome (CBS) | Apraxia, cortical sensory loss, alien limb phenomenon, unilateral dystonia, poor levodopa response | G23.8 |
| Normal pressure hydrocephalus (NPH) | Classic triad: gait instability, urinary incontinence, dementia; wide-based shuffling gait; MRI shows ventricular enlargement | G91.2 |
| Postencephalitic parkinsonism (G21.3) | History of encephalitis, may follow viral illness, oculogyric crises, dystonia, may have prolonged course | G21.3 |
📋 Clinical Indicators
| Clinical Indicator | Coding/Documentation Impact | Action Required |
|---|---|---|
| Tremor-dominant vs. PIGD phenotype | Tremor-dominant = better prognosis; PIGD = higher fall risk, faster cognitive decline — both affect DRG and care intensity | Query for phenotype if not documented |
| Presence of dyskinesia (G20.B1/G20.B2) | Selects B-series subcodes vs. A-series; indicates advanced disease and levodopa complications | Document per each encounter — dyskinesia may fluctuate |
| Motor fluctuations / “off” episodes (G20.A2/G20.B2) | Selects “with fluctuations” subcodes; affects medication management complexity | Query if not explicitly stated; review medication timing notes |
| Dementia with Parkinson’s (F02.x) | Requires etiology/manifestation coding: G20.x sequenced first, F02.80/F02.81x second; affects HCC for cognitive complexity | Document severity and behavioral disturbance status |
| Behavioral/psychological symptoms with dementia (F02.811, F02.818, F02.82–F02.84, or F02.A-/F02.B-/F02.C- codes) | Select based on documented dementia severity and symptom type: agitation (including aggressive/combative behavior), other behavioral disturbance, psychotic disturbance, mood disturbance, or anxiety | Query for dementia severity and the specific behavioral/psychological symptom |
| Hoehn-Yahr stage documented | Stage 3–5 supports medical necessity for PT/OT, DBS evaluation, home health, SNF | Ensure stage appears in assessment/plan |
| Dysphagia (R13.1x) present | Additional code required; drives swallowing/SLP therapy documentation (e.g., 92526 for swallowing dysfunction; for PD-related voice treatment in 2027, 92662/+92663 may apply) and aspiration precautions; increases aspiration pneumonia risk (J69.0) | Specify severity: R13.10 (unspecified), R13.11 (oral phase), R13.12 (oropharyngeal), R13.13 (pharyngeal), R13.14 (pharyngoesophageal) |
| DBS implant status or device-management encounter | Z96.82 identifies presence of a neurostimulator, including a brain neurostimulator; Z45.42 identifies an encounter for adjustment and management of a neurostimulator; use T85.- codes for documented device complications | Code underlying PD when clinically relevant; use Z45.42 for DBS programming/management encounters and Z96.82 for device presence/status when applicable |
| Falls (W19.xxXA) | External cause code; supplemental to the diagnosis, symptom, injury, or other reason for the encounter and never reported as principal/first-listed | Use when a fall is the external cause for the encounter; code the injury/condition if applicable and use Z91.81 for history/risk of falling when no current fall event is being coded |
| Idiopathic (G20.x) vs. secondary (G21.x) vs. Parkinson-plus (G23.x) | Different HCC weights; different prognosis; DBS coverage requires idiopathic PD specifically | Ensure clear documentation of etiology; query if unclear |
- 92507: Treatment of speech, language, voice, communication, and/or auditory processing disorder; individual; deleted for CPT 2027 and replaced by the new individual speech-language pathology treatment code family 92654–92663.
When the record documents parkinsonism, tremor, or bradykinesia without specifying idiopathic vs. secondary vs. Parkinson-plus, or when the chart mentions only “parkinsonism” — consider a clarification query. The April 2026 ICD-10-CM index update makes this distinction critical: “Parkinson’s disease” routes to G20.A1 while “parkinsonism” routes to the G21 category. Per UASI Solutions, provider terminology must match the intended diagnosis.
🦴 Anatomy & Pathophysiology
Parkinson’s disease primarily affects the substantia nigra pars compacta (SNpc), a midbrain nucleus responsible for producing dopamine that projects to the striatum (caudate nucleus and putamen) via the nigrostriatal pathway. Loss of approximately 60–80% of SNpc dopaminergic neurons is required before clinical motor symptoms emerge, reflecting the brain’s compensatory capacity.
Core Pathology
- Lewy bodies: Eosinophilic intracellular inclusions containing misfolded alpha-synuclein protein. Per the Parkinson’s Foundation, these aggregates disrupt neuronal function and are the pathological hallmark of both PD and Dementia with Lewy Bodies (DLB).
- Braak staging: Alpha-synuclein pathology spreads in a predictable pattern (Braak stages 1–6), beginning in the olfactory bulb and dorsal motor nucleus (explaining anosmia and autonomic symptoms pre-dating motor features), ascending to substantia nigra (motor symptoms), and eventually involving the neocortex (dementia).
Basal Ganglia Circuit Disruption
Normal motor control requires a balance between the direct pathway (facilitating movement, dopamine D1 receptor-mediated) and the indirect pathway (suppressing unwanted movement, dopamine D2 receptor-mediated). Dopamine depletion increases inhibitory output from the globus pallidus internus (GPi) and subthalamic nucleus (STN) to the thalamus, reducing thalamo-cortical activation and producing bradykinesia and rigidity. Deep brain stimulation targets the STN or GPi to modulate this abnormal inhibitory output.
Parkinson-Plus Syndromes: Key Pathological Differences
- PSP (G23.1): Tau protein accumulation (tauopathy); affects the subthalamic nucleus, globus pallidus, superior colliculus; explains vertical gaze palsy
- MSA / striatonigral degeneration (G90.3 or G23.2, depending on documentation): Alpha-synuclein oligodendroglial inclusions (glial cytoplasmic inclusions); involves striatonigral system (parkinsonian-predominant features) and olivopontocerebellar system (cerebellar-predominant features). Do not use G23.3 for MSA-P/MSA-C in ICD-10-CM.
- DLB (G31.83): Widespread cortical Lewy body pathology; overlaps with PD but dementia onset precedes or coincides with motor features
💊 Medication Impact / Treatment
Dopaminergic Pharmacotherapy
Levodopa combined with carbidopa (the decarboxylase inhibitor) remains the most effective symptomatic treatment. Levodopa-carbidopa intestinal gel (Duopa, HCPCS J7340) is indicated for advanced PD with severe motor fluctuations via continuous jejunal infusion. Per FDA labeling, motor fluctuation documentation is essential to justify Duopa therapy.
| Drug Class | Examples | Coding/Documentation Impact |
|---|---|---|
| Levodopa/carbidopa (oral) | Sinemet, Rytary (extended release) | Wearing-off → G20.A2; dyskinesia → G20.B1/B2; document “with fluctuations” if applicable |
| Levodopa/carbidopa intestinal gel | Duopa (J7340) | Advanced PD indicator; requires gastrostomy; document severe motor fluctuations |
| Dopamine agonists | Pramipexole (Mirapex), ropinirole (Requip), rotigotine patch (Neupro) | Impulse control disorders as adverse effects — code separately if documented |
| MAO-B inhibitors | Selegiline, rasagiline (Azilect), safinamide (Xadago) | Drug interactions with opioids, antidepressants — document for MDM complexity |
| COMT inhibitors | Entacapone (Comtan), opicapone (Ongentys) | Used to extend levodopa effect; dyskinesia may increase — affects G20.B subcode |
| Amantadine (extended release) | Gocovri, Osmolex ER | Used specifically to reduce dyskinesia — presence confirms G20.B coding |
| Subcutaneous apomorphine | Apokyn (HCPCS J0364) | On-demand for “off” episodes; requires documented “off” episodes → G20.A2/G20.B2 |
| Anticholinergics | Trihexyphenidyl, benztropine | Used for tremor; cognitive side effects in elderly; contraindicated in PDD |
| Antipsychotics (PD-safe) | Quetiapine (low dose), pimavanserin (Nuplazid) | Pimavanserin specifically for PD psychosis — document hallucinations for medical necessity |
Wearing-off and dyskinesia in PD are disease progression phenomena, not adverse drug effects. Per Practical Neurology, coding these as T42.8X5 (adverse effect of antiparkinsonism drugs) is incorrect. “Off” episodes and levodopa-induced dyskinesia should be captured through the G20.A2, G20.B1, or G20.B2 subcodes based on clinical features, not adverse effect codes.
Preview ends here. The full guide continues with FY2027 ICD-10-CM code sets, CPT surgical coding, MS-DRG mapping, reimbursement guidance, CDI query templates, and an audit checklist — all available to CCO Members.
← Back to All Clinical Documentation Guides
📘 ICD-10-CM Guidelines
Etiology/Manifestation Convention — Parkinson’s Disease with Dementia
Per the FY2027 ICD-10-CM Official Guidelines for Coding and Reporting, the etiology/manifestation convention is explicitly illustrated with Parkinson’s disease as an example. When dementia accompanies Parkinson’s disease:
- The underlying etiology code from category G20.- (Parkinson’s disease) is sequenced first
- The manifestation code from category F02.- (dementia in other diseases classified elsewhere) is sequenced second, in brackets in the Alphabetic Index
FY2026 G20 Subcode Structure — Dyskinesia and Fluctuations
Effective October 1, 2023 (FY2024) and continuing through FY2027, category G20 contains subcodes capturing motor complication status. As of the April 1, 2026 ICD-10-CM Index update, and continuing in FY2027, a documented diagnosis of “Parkinson’s disease” directs coders to G20.A1 unless dyskinesia or fluctuations are documented:
The ICD-10-CM Alphabetic Index was revised effective April 1, 2026: the main term “Parkinson’s disease, syndrome, or tremor — see Parkinsonism” was deleted and replaced by two separate main terms:
- Parkinson’s disease → See Disease, Parkinson’s → leads to G20.A1
- Parkinson’s syndrome or tremor → See Parkinsonism → leads to G21 category
This means documentation of “Parkinson’s disease” now codes more specifically than “parkinsonism.” Coders must verify exact provider language before code selection. Source: UASI Solutions April 2026 ICD-10-CM Update.
Key Guidelines for Parkinson’s-Related Coding
- Code also dementia: When Parkinson’s disease is documented with dementia, sequence the G20.- etiology code first, followed by the appropriate F02.- manifestation code. Select the F02 code by documented severity and behavioral/psychological symptoms (e.g., F02.80, F02.811, F02.818, F02.82–F02.84, or the applicable F02.A-/F02.B-/F02.C- code).
- Secondary parkinsonism: For G21.x codes, code also the adverse effect or underlying condition (e.g., adverse effect of drug code T code, or underlying disease code).
- Dementia with Lewy bodies (G31.83): Code also, when applicable, dementia with behavioral disturbance (F02.81x) or without behavioral disturbance (F02.80).
- REM sleep behavior disorder: G47.52 may be coded additionally and is clinically significant as a pre-motor PD marker.
- Dysphagia in PD: R13.1x is coded additionally; if aspiration pneumonia (J69.0) is documented, it should be coded as an additional diagnosis.
- Falls: W19.xxxA is an external cause code and is supplemental to the diagnosis, symptom, injury, or other reason for the encounter; use Z91.81 for history/risk of falling when no current fall event is being coded.
- Code specificity requirement: Per FY2027 Official Guidelines, codes must be reported at the highest level of specificity documented. For G20, this means selecting the appropriate subcode (G20.A1, G20.A2, G20.B1, G20.B2, or G20.C) based on provider documentation of dyskinesia and motor fluctuations.
🔢 ICD-10-CM Code Set (Tabular)
Primary Parkinson’s Disease (G20.-) — FY2027 Subcodes
| Code | Description | Clinical Notes / FY2026 Changes |
|---|---|---|
| G20.A1 | Parkinson’s disease without dyskinesia, without mention of fluctuations | Default for documented “Parkinson’s disease” per April 2026 Index; early-to-moderate PD without motor complications; Hoehn-Yahr 1–2 typical |
| G20.A2 | Parkinson’s disease without dyskinesia, with fluctuations | Motor fluctuations (“off” episodes, wearing-off) present but no dyskinesia; requires explicit documentation of fluctuations |
| G20.B1 | Parkinson’s disease with dyskinesia, without mention of fluctuations | Levodopa-induced dyskinesia documented; advanced disease; amantadine (Gocovri) use confirms; requires documentation of involuntary movements |
| G20.B2 | Parkinson’s disease with dyskinesia, with fluctuations | Most advanced motor complication profile; both dyskinesia AND “off” periods documented; may indicate Duopa (J7340) or DBS candidacy |
| G20.C | Parkinsonism, unspecified | Used when type of parkinsonism cannot be determined or specified; NOT the default for documented “Parkinson’s disease” after April 2026 |
Secondary Parkinsonism (G21.-)
| Code | Description | Notes |
|---|---|---|
| G21.0 | Malignant neuroleptic syndrome (NMS) | Life-threatening; hyperthermia, rigidity, autonomic instability; code also adverse effect of drug (T43.x) |
| G21.11 | Neuroleptic-induced parkinsonism | Due to antipsychotics, metoclopramide; code also adverse effect T43.3×5, T43.4×5, T43.505 etc. |
| G21.19 | Other drug-induced secondary parkinsonism | Other medications (e.g., valproate, lithium, calcium channel blockers); code also adverse effect T-code |
| G21.2 | Secondary parkinsonism due to other external agents | Toxins (MPTP, manganese); code also underlying external agent |
| G21.3 | Postencephalitic parkinsonism | After viral encephalitis; historical encephalitis lethargica; document prior encephalitis history |
| G21.4 | Vascular parkinsonism | Cerebrovascular disease causing parkinsonian features; code also cerebrovascular condition |
| G21.8 | Other secondary parkinsonism | Includes trauma-induced, tumor-related; code underlying cause |
| G21.9 | Secondary parkinsonism, unspecified | Avoid if specific cause can be determined |
Degenerative Basal Ganglia Diseases / Parkinson-Plus (G23.-)
| Code | Description | Notes |
|---|---|---|
| G23.0 | Hallervorden-Spatz disease | Now called NBIA / PANK2; iron accumulation in basal ganglia; presents in childhood/young adults |
| G23.1 | Progressive supranuclear palsy (PSP) | Tauopathy; vertical gaze palsy; axial rigidity; early falls; poor levodopa response; HCC maps same as G20 |
| G23.2 | Striatonigral degeneration | Parkinsonian-predominant degenerative syndrome; may be described clinically as a multiple system atrophy variant when documented; HCC-mapped |
| G23.3 | Hypomyelination with atrophy of the basal ganglia and cerebellum | Do not use for MSA-P/MSA-C unless the provider specifically documents H-ABC/hypomyelination with atrophy of the basal ganglia and cerebellum; HCC-mapped |
| G23.8 | Other specified degenerative diseases of basal ganglia | Includes corticobasal degeneration (CBD); specify in documentation |
| G23.9 | Degenerative disease of basal ganglia, unspecified | Avoid when more specific diagnosis available |
Lewy Body Dementia
| Code | Description | Notes |
|---|---|---|
| G31.83 | Dementia with Lewy bodies (DLB) | Code also F02.80 or F02.81x for dementia manifestation; distinguished from PDD by earlier onset of dementia relative to motor features (within 1 year) |
Dementia Manifestation Codes (F02.-) — Sequence After G20.x or G31.83
| Code | Description | Notes |
|---|---|---|
| F02.80 | Dementia in other diseases classified elsewhere, unspecified severity, without behavioral disturbance, psychotic features, agitation, or other behavioral/psychological symptoms of dementia | Sequence after G20.x; basic PDD without behavioral complications |
| F02.811 | Dementia in other diseases classified elsewhere, unspecified severity, with agitation | Use for agitation/aggression/combative behavior when severity is unspecified; for documented mild/moderate/severe dementia, use the corresponding F02.A11/F02.B11/F02.C11 code |
| F02.818 | Dementia in other diseases classified elsewhere, unspecified severity, with other behavioral disturbance | Use for other specified behavioral disturbance when severity is unspecified; for documented mild/moderate/severe dementia, use the corresponding F02.A18/F02.B18/F02.C18 code |
| F02.82 | Dementia in other diseases classified elsewhere, unspecified severity, with psychotic disturbance | Hallucinations, paranoia, suspiciousness, or delusions — commonly visual in PDD; for documented mild/moderate/severe dementia, use the corresponding F02.A2/F02.B2/F02.C2 code |
| F02.83 | Dementia in other diseases classified elsewhere, unspecified severity, with mood disturbance | Depression, apathy, or anhedonia; for documented mild/moderate/severe dementia, use the corresponding F02.A3/F02.B3/F02.C3 code |
| F02.84 | Dementia in other diseases classified elsewhere, unspecified severity, with anxiety | Use when dementia in Parkinson’s disease or another classified disease is documented with anxiety and severity is unspecified; for documented mild/moderate/severe dementia, use the corresponding F02.A4/F02.B4/F02.C4 code |
| F02.A–F02.C | Expanded codes for mild/moderate/severe severity with various behavioral features | FY2024 expansion; select based on documented MMSE/MoCA severity when available |
Additional Secondary Diagnosis Codes
| Code | Description | Clinical Context |
|---|---|---|
| R13.10–R13.14 | Dysphagia (unspecified, oral phase, oropharyngeal, pharyngeal, pharyngoesophageal) | Common in moderate-advanced PD; drives speech therapy and aspiration precautions |
| J69.0 | Pneumonitis due to inhalation of food and vomit (aspiration pneumonia) | Leading cause of death in advanced PD; sequence after dysphagia if applicable |
| W19.xxXA | Unspecified fall, initial encounter | Falls are prevalent; document fall history, POA status; pair with injury code or other condition code when applicable |
| G47.52 | REM sleep behavior disorder | Pre-motor PD biomarker; may precede diagnosis by years; document when present |
| F32.x / F33.x | Major depressive disorder, single/recurrent episode | Depression in 40–50% of PD patients; must specify severity for HCC v28 qualification |
| K59.00 | Constipation, unspecified (or K59.09 other) | Autonomic dysfunction; very common; use K59.01 (slow transit) if documented |
| N39.41 | Urge incontinence | Autonomic dysfunction in PD/MSA; N39.46 (mixed) if stress component also documented |
| Z45.49 | Encounter for adjustment and management of other implanted nervous system device | Use for DBS programming/management encounters; primary Dx remains G20.x |
🔎 Indexing
The following index pathways are critical for FY2027 accurate code assignment and reflect the April 1, 2026 ICD-10-CM Index update carried forward into the FY2027 code set:
| Provider Documents | Index Pathway (April 2026+) | Resulting Code |
|---|---|---|
| “Parkinson’s disease” | Main term: Parkinson’s disease → See Disease, Parkinson’s → without dyskinesia, without fluctuations | G20.A1 |
| “Parkinson’s disease with dyskinesia” | Disease, Parkinson’s → with dyskinesia → without fluctuations | G20.B1 |
| “Parkinson’s disease with dyskinesia and motor fluctuations” | Disease, Parkinson’s → with dyskinesia → with fluctuations | G20.B2 |
| “Parkinson’s disease with wearing-off” / “off episodes” | Disease, Parkinson’s → without dyskinesia → with fluctuations | G20.A2 |
| “Parkinsonism” (unspecified) | Main term: Parkinsonism → unspecified | G20.C |
| “Neuroleptic parkinsonism” / “drug-induced parkinsonism” | Parkinsonism → due to → drug-induced → neuroleptic | G21.11 |
| “Vascular parkinsonism” | Parkinsonism → vascular | G21.4 |
| “Progressive supranuclear palsy” | Palsy → supranuclear, progressive (nuclear) → NEC | G23.1 |
| “Multiple system atrophy” / “striatonigral degeneration” | Atrophy → system → multiple, or Degeneration → striatonigral; verify in the FY2027 Alphabetic Index and Tabular List | G90.3 for multi-system degeneration of the autonomic nervous system; G23.2 for striatonigral degeneration |
| “Dementia with Parkinson’s disease” | Disease, Parkinson’s [G20.-] → code also F02.80 or F02.81- | G20.x + F02.80/F02.81x |
| “Dementia with Lewy bodies” | Dementia → Lewy body | G31.83 + F02.80/F02.81x |
🏥 CPT
Deep Brain Stimulation (DBS) — Surgical Procedures
DBS is indicated for idiopathic Parkinson’s disease (G20.x) with inadequate medication response. Per the Boston Scientific 2026 DBS Reimbursement Guide and the Medtronic 2026 DBS Coding Guide, coverage requires idiopathic PD (G20.x). Non-idiopathic Parkinson’s or Parkinson-plus syndromes (G23.x) are contraindications to DBS coverage by most payers.
| CPT Code | Description | Global Period | 2026 Medicare Facility Rate |
|---|---|---|---|
| 61863 | Stereotactic implantation of neurostimulator electrode array in subcortical site (e.g., STN, GPi, thalamus), without intraoperative microelectrode recording; first array | 090 | $1,496 |
| 61864 | Each additional array (add-on to 61863) | ZZZ | $259 |
| 61867 | Same as 61863 but with intraoperative microelectrode recording; first array | 090 | $2,206 |
| 61868 | Each additional array with microelectrode recording (add-on to 61867) | ZZZ | $456 |
| 61885 | Insertion or replacement of cranial neurostimulator pulse generator or receiver; with connection to single electrode array | 090 | $558 (physician); $31,526 HOPPS APC 5465 |
| 61886 | Insertion or replacement of cranial neurostimulator pulse generator; with connection to 2 or more electrode arrays (bilateral DBS) | 090 | $932 (physician); $31,526 HOPPS APC 5465 |
| 61880 | Revision or removal of intracranial neurostimulator electrodes | 090 | $620 (physician); $3,572 HOPPS |
| 61888 | Revision or removal of cranial neurostimulator pulse generator or receiver | 090 | $403 (physician); $11,384 HOPPS APC 5463 |
DBS Programming and Analysis
| CPT Code | Description | 2026 Medicare Rate (Non-Fac / Fac) | Notes |
|---|---|---|---|
| 95970 | Electronic analysis of implanted neurostimulator pulse generator/transmitter, brain/CNS; without programming | $20 / $16 | Analysis only, no adjustments made |
| 95983 | Brain neurostimulator programming, first 15 minutes face-to-face time | $52 / $42 | Replaces legacy 95971; time-based billing |
| 95984 | Brain neurostimulator programming, each additional 15 minutes (add-on) | $45 / $37 | Replaces legacy 95972; add-on to 95983 |
The old DBS programming codes 95971 and 95972 have been replaced by 95983 and 95984 for brain neurostimulator programming. Per the Medtronic 2026 coding guide, using the old codes will result in claim denial. Use 95983 for the first 15 minutes and 95984 for each additional 15-minute increment.
Physical, Speech, and Psychiatric Therapy Codes
| CPT Code | Description | Relevance to Parkinson’s |
|---|---|---|
| 97110 | Therapeutic procedure; therapeutic exercises | BIG therapy (LSVT BIG) — amplitude-based PT for PD; requires separate units per 15 min |
| 97112 | Neuromuscular reeducation of movement, balance, coordination | Gait training, balance retraining for PIGD variant |
| 92662 / +92663 | Speech-language pathology treatment for voice, upper airway dysfunction, and/or resonance disorders; initial 30 minutes / each additional 15 minutes | LSVT LOUD/voice therapy for hypophonia in PD; report the base code for the initial 30 minutes and the add-on code for each additional 15 minutes when supported |
| 92521 | Evaluation of speech fluency (e.g., stuttering) | Speech evaluation for dysarthria; use with G20.x Dx |
| 90791 | Psychiatric diagnostic evaluation | Cognitive/behavioral evaluation; use when dementia or psychosis evaluation performed |
| 90792 | Psychiatric diagnostic evaluation with medical services | When prescribing provider performs evaluation; document PDD, depression, or psychosis |
| 96132 | Neuropsychological testing evaluation services by physician or other qualified professional, first hour | Baseline and serial cognitive assessment in PD dementia progression monitoring |
| 95958 | Wada activation test for hemispheric function, including EEG monitoring | Not a Parkinson’s wearable-monitoring code; generally not used for PD symptom monitoring |
- 92507: Treatment of speech, language, voice, communication, and/or auditory processing disorder; individual; deleted for CPT 2027.
- 92654–92663: new individual speech-language pathology treatment code family for CPT 2027; not reportable for 2026 dates of service.
- 92662/+92663: voice, upper airway dysfunction, and/or resonance disorder treatment category used for PD hypophonia/LSVT LOUD when supported by documentation.
🧾 HCPCS
| HCPCS Code | Description | Typical Use in Parkinson’s |
|---|---|---|
| L8679 | Implantable neurostimulator pulse generator, any type | DBS pulse generator (IPG) — general code when specific model not otherwise classified |
| L8686 | Implantable neurostimulator pulse generator, single array, non-rechargeable, includes extension | Single-array (unilateral) non-rechargeable DBS IPG |
| L8687 | Implantable neurostimulator pulse generator, dual array, rechargeable, includes extension | Bilateral rechargeable DBS (most common current device) |
| L8688 | Implantable neurostimulator pulse generator, dual array, non-rechargeable, includes extension | Bilateral non-rechargeable DBS IPG |
| L8681 | Patient programmer (external) for use with implantable programmable neurostimulator, replacement only | Patient handheld controller replacement |
| L8689 | External recharging system for battery (internal), replacement only | Replacement recharging system for rechargeable DBS |
| C1767 | Generator, neurostimulator (implantable), non-rechargeable | Hospital outpatient (HOPPS) device reporting for non-rechargeable DBS |
| C1820 | Generator, neurostimulator (implantable), non-high frequency with rechargeable battery and charging system | HOPPS device reporting for rechargeable DBS |
| C1883 | Adaptor/extension, pacing lead or neurostimulator lead (implantable) | Extension cables between electrode and IPG |
| J7340 | Carbidopa/levodopa enteral suspension, 5 mg/20 mg per mL, 1 mL (Duopa) | Advanced PD with severe motor fluctuations; continuous intestinal infusion via PEG-J; requires documented G20.A2 or G20.B2 |
| J3490 | Unclassified drugs | Use only when no specific HCPCS Level II code applies; apomorphine injection is reported with J0364 when payer policy recognizes the specific code |
Duopa (levodopa-carbidopa intestinal gel) HCPCS J7340 requires documentation of advanced idiopathic PD with severe motor fluctuations that are not adequately controlled with optimized oral therapy. The diagnosis should reflect G20.A2 (without dyskinesia, with fluctuations) or G20.B2 (with dyskinesia, with fluctuations). Documentation of specific “off” times per day (typically ≥3 hours) and failed oral regimen optimization is essential for prior authorization and claim support. Per FDA labeling for Duopa, the indication is advanced PD.
📚 AHA Coding Clinic
| Topic | Guidance Summary | Reference |
|---|---|---|
| Parkinson’s disease with dementia sequencing | When a patient has Parkinson’s disease with dementia, G20.- is sequenced as the etiology code first, followed by F02.80 or F02.81- as the manifestation code. This reflects the etiology/manifestation convention per ICD-10-CM Official Guidelines. | AHA Coding Clinic; confirmed in FY2026 Official Guidelines (CMS, Section I.A.13) |
| Dementia with Lewy bodies vs. Parkinson’s dementia | Dementia with Lewy bodies (G31.83) is a distinct entity from Parkinson’s disease dementia. DLB is coded G31.83 with additional code for dementia manifestation F02.80/F02.81x. Parkinson’s disease dementia uses G20.x + F02.x. Clinical differentiation based on temporal onset is key — DLB dementia onset precedes or is concurrent with motor features (within 1 year). | AHA Coding Clinic guidance; Parkinson’s Foundation clinical criteria |
| Drug-induced parkinsonism vs. idiopathic PD | G21.11 (neuroleptic-induced) or G21.19 (other drug-induced) are correct codes when parkinsonian symptoms are clearly attributable to a medication. The adverse effect T-code for the causative drug should also be reported. Do not assign G20.x when a drug etiology has been established. | AHA Coding Clinic; Official Guidelines Ch. 19 (adverse effects) |
| Aspiration pneumonia in PD | Aspiration pneumonia (J69.0) should be coded when documented by the provider. Dysphagia (R13.1x) should be coded additionally as the underlying cause when applicable. The PD code (G20.x) is also reported as a contributing condition. | AHA Coding Clinic guidance on aspiration pneumonia sequencing |
| FY2024 G20 subcode expansion — ongoing guidance | Since October 2023, coders should document and query for dyskinesia and motor fluctuation status to assign the appropriate G20 subcode. If not documented, query the provider or use G20.A1 (without dyskinesia/fluctuations) as the default per current index routing. Coding Clinic has emphasized that documentation specificity is required for subcode differentiation. | AHA Coding Clinic guidance following FY2024 G20 expansion; UASI April 2026 index update |
💰 HCC / Risk Adjustment
Parkinson disease and dementia map to separate V28 HCCs. Mappings below follow the 2024 CMS-HCC model (commonly called V28), which CMS uses at 100 percent for non-PACE Medicare Advantage risk scores and continued for CY 2027, and the CMS 2027 Initial ICD-10-CM Mappings. Coefficients vary by enrollee segment and payer, so this guide does not quote RAF weights; check the current CMS model software. Hierarchies are applied by CMS after coding: code every documented, supported condition.
| ICD-10-CM Code(s) | Description | V28 HCC | Coding / Documentation Notes |
|---|---|---|---|
| G20.A1, G20.A2, G20.B1, G20.B2, G20.C | Parkinson’s disease (with or without dyskinesia and fluctuations); parkinsonism, unspecified | HCC 199 — Parkinson and Other Degenerative Disease of Basal Ganglia | — |
| G21.3, G21.4, G21.8, G21.9, G23.-, G90.3 | Postencephalitic, vascular, other, and unspecified secondary parkinsonism; other basal ganglia degeneration; multiple system atrophy | HCC 199 | — |
| G21.0, G21.1-, G21.2 | Malignant neuroleptic syndrome; drug-induced and other external-agent parkinsonism | No V28 payment HCC | — |
| G31.83 | Neurocognitive disorder with Lewy bodies | HCC 127 — Dementia, Mild or Unspecified | Code also the F02 code with the documented severity |
| F02.8-, F02.A-, F02.B-, F02.C- | Dementia in other diseases (unspecified or mild; moderate; severe) | HCC 127; HCC 126; HCC 125 | With G20, code also F02 per the Tabular note |
Sources: CMS 2027 Initial ICD-10-CM Mappings (2024 CMS-HCC model, V28); CMS CY 2024 Rate Announcement, Attachment VI (hierarchies, interactions); FY 2027 ICD-10-CM Tabular List, Index, and Official Guidelines. Verified November 3, 2026.
✍️ CDI Query Templates
| Scenario | AHIMA/ACDIS-Compliant Query Wording |
|---|---|
| Clarify PD subtype (idiopathic vs. secondary vs. Parkinson-plus) | “The medical record documents parkinsonism/tremor/bradykinesia in this patient. For accurate clinical documentation and coding, could you please clarify whether this represents: (A) Idiopathic Parkinson’s disease (primary), (B) Secondary parkinsonism (please specify cause: drug-induced, vascular, other), (C) Parkinson-plus syndrome such as PSP or MSA, (D) Unable to determine based on current information.” |
| Identify dyskinesia and motor fluctuations for G20 subcode | “For this patient with documented Parkinson’s disease, the record mentions involuntary movements/motor symptoms. Could you clarify: (A) Parkinson’s disease without dyskinesia, without motor fluctuations (stable medication response), (B) Parkinson’s disease without dyskinesia, but with motor fluctuations/wearing-off/off episodes, (C) Parkinson’s disease with dyskinesia (levodopa-induced involuntary movements), without fluctuations, (D) Parkinson’s disease with dyskinesia and motor fluctuations/off episodes.” |
| Cognitive status / dementia in PD | “The patient with Parkinson’s disease appears to have cognitive impairment noted in the record. Could you clarify whether the patient has: (A) Mild cognitive impairment (not meeting dementia criteria), (B) Parkinson’s disease dementia (PDD) — cognitive decline severe enough to impact daily function, (C) Dementia with Lewy bodies (DLB) — if dementia preceded or was concurrent with motor symptoms, (D) No clinically significant cognitive impairment at this time.” |
| Behavioral/psychological symptom and severity specificity in PDD | “The record documents Parkinson’s disease dementia. Could you please indicate the dementia severity (unspecified, mild, moderate, or severe) and whether behavioral or psychological symptoms are present: (A) No behavioral disturbance, psychotic disturbance, mood disturbance, or anxiety, (B) With agitation (including combative/aggressive behavior), (C) With psychotic disturbance (hallucinations, paranoia, delusions), (D) With mood disturbance (depression, apathy, anhedonia), (E) With anxiety, (F) With other behavioral disturbance (please specify), (G) Unable to determine.” |
| Dysphagia severity and type | “Dysphagia is noted in a patient with Parkinson’s disease. Could you specify: (A) Dysphagia, unspecified, (B) Oral phase dysphagia, (C) Oropharyngeal dysphagia, (D) Pharyngeal dysphagia, (E) Pharyngoesophageal dysphagia, (F) Aspiration, with or without aspiration pneumonia.” |
| Depression severity (HCC v28 qualification) | “The patient has documented depression in the setting of Parkinson’s disease. For accurate coding under CMS-HCC v28, only moderate to severe major depression is risk-adjustable. Could you clarify: (A) Mild major depressive episode (single or recurrent), (B) Moderate major depressive episode (single or recurrent), (C) Severe major depressive episode (with or without psychotic features), (D) Depressive disorder, not otherwise specified, (E) Adjustment disorder with depressed mood.” |
When a patient with Parkinson’s disease is being evaluated for deep brain stimulation (DBS) and the record includes dementia, depression, or documents “Parkinson-plus” features, ensure these are clearly documented. Per the Boston Scientific 2026 DBS Reimbursement Guide, DBS coverage requires idiopathic PD; cognitive impairment, psychosis, and non-idiopathic parkinsonism are contraindications. Documentation of the PD subtype (idiopathic G20.x) is essential for DBS prior authorization and claim support.
🧑⚕️ Treatments (Clinical)
Pharmacological Management
According to the American Academy of Neurology (AAN) guidelines for Parkinson’s disease, management is staged by disease progression:
- Early PD: Dopamine agonists (pramipexole, ropinirole, rotigotine) or levodopa/carbidopa for motor symptom control. MAO-B inhibitors (rasagiline, safinamide) as adjunctive or monotherapy in mild disease.
- Moderate PD with fluctuations: Levodopa dose optimization; addition of COMT inhibitors (entacapone, opicapone) or MAO-B inhibitors to extend levodopa effect. Rotigotine transdermal patch for continuous dopaminergic stimulation.
- Advanced PD (G20.B2): Duopa (carbidopa-levodopa intestinal gel, J7340) for continuous jejunal infusion; subcutaneous apomorphine (Apokyn) for acute “off” episodes; DBS evaluation when medications inadequate.
- Dyskinesia management: Amantadine extended-release (Gocovri, Osmolex ER) — FDA-approved for levodopa-induced dyskinesia; dose timing adjustments.
- Psychosis in PD: Reduce or stop anticholinergics, amantadine; use clozapine (with monitoring) or pimavanserin (Nuplazid) — the only FDA-approved agent for PD-related psychosis.
- PD dementia: Rivastigmine (FDA-approved for PDD) — the only cholinesterase inhibitor with a specific PDD indication.
Surgical Management
Deep brain stimulation (DBS) is the gold standard surgical treatment for idiopathic PD meeting criteria. Key surgical targets include:
- Subthalamic nucleus (STN): Most common target; effective for tremor, rigidity, bradykinesia, reduces medication requirements
- Globus pallidus internus (GPi): Preferred when dyskinesia is the predominant complication; may be better for patients with cognitive concerns
- Ventral intermediate nucleus of thalamus (Vim): Used primarily for tremor-dominant PD
DBS patient selection criteria per AAN/Movement Disorder Society: idiopathic PD diagnosis (G20.x), demonstrated levodopa responsiveness, absence of significant cognitive impairment, adequate social/caregiver support, Hoehn-Yahr stage 2–4 typically.
Rehabilitation Therapies
- LSVT BIG (CPT 97110, 97112): Evidence-based amplitude-oriented physical therapy designed for PD gait and movement; intensive outpatient program; per LSVT Global, improves motor function across all Hoehn-Yahr stages
- LSVT LOUD (CPT 92662/+92663 for 2027 voice/resonance treatment when supported): Intensive voice therapy targeting hypophonia and speech deficits; 16-session protocol; evidence base from multiple randomized controlled trials
- Exercise: High-intensity aerobic exercise (cycling, boxing-based programs like Rock Steady Boxing) shows neuroprotective and symptomatic benefits; refer to exercise as medicine framework
- Occupational therapy: ADL adaptation, home safety, driving evaluation, adaptive equipment
- 92507: Treatment of speech, language, voice, communication, and/or auditory processing disorder; individual; deleted for CPT 2027.
- 92662/+92663: new for CPT 2027 voice, upper airway dysfunction, and/or resonance disorder treatment; not reportable for 2026 dates of service.
Management of Non-Motor Complications
- Constipation (K59.00): Polyethylene glycol (MiraLax), increased fiber, hydration; avoid bulk-forming agents without adequate hydration
- Orthostatic hypotension: Fludrocortisone, midodrine, droxidopa (Northera) — especially in MSA; compression stockings, salt supplementation
- Urinary incontinence (N39.41): Anticholinergics (with caution — cognitive effects); mirabegron (beta-3 agonist) preferred in PD; botulinum toxin for refractory cases
- REM sleep behavior disorder (G47.52): Clonazepam (low dose), melatonin; bed-safety measures; iron supplementation in some cases
- Depression (F32.x/F33.x): SNRIs (venlafaxine) or SSRIs; nortriptyline may improve both depression and pain; pramipexole has antidepressant properties
🎓 Patient Education / Summary
Parkinson’s disease is a lifelong, progressive condition. While there is currently no cure, significant quality-of-life improvements are achievable with optimal treatment. Key patient education points supported by the Parkinson’s Foundation and the American Parkinson Disease Association (APDA):
Understanding Your Diagnosis
- Parkinson’s disease is a brain condition caused by loss of dopamine-producing cells. It is not contagious and is not directly caused by anything you did.
- Parkinson’s progresses at different rates for different people. Many people live independently for years or decades after diagnosis.
- The disease affects movement (tremor, stiffness, slowness) but also many non-motor functions including sleep, digestion, mood, and cognition.
Medication Management
- Take levodopa/carbidopa on a strict schedule — timing relative to meals matters (high-protein meals can impair absorption).
- Never stop Parkinson’s medications suddenly without medical guidance — abrupt discontinuation can cause a life-threatening condition (neuroleptic malignant syndrome-like presentation).
- Report any involuntary movements (dyskinesia) or periods when medications seem less effective (“off” times) to your neurologist immediately — these may require medication adjustments and affect your diagnosis code.
- Avoid antipsychotic medications (haloperidol, risperidone, olanzapine) for behavioral symptoms unless supervised by your movement disorder specialist — these can dramatically worsen Parkinson’s symptoms.
Exercise and Lifestyle
- Regular aerobic exercise (walking, cycling, swimming, boxing-based programs) is one of the most effective tools for slowing functional decline. Aim for 150 minutes per week of moderate-intensity activity.
- LSVT BIG (physical therapy) and LSVT LOUD (speech therapy) are specialized, proven programs for Parkinson’s — ask your care team for a referral.
- Fall prevention is critical: remove home hazards (rugs, clutter), use nightlights, install grab bars, consider a walker or cane when balance is affected. Report all falls to your medical team.
When to Seek Emergency Care
- Sudden severe stiffness or inability to move combined with high fever — this may indicate a medication emergency
- Choking, difficulty swallowing liquids or solids — increased aspiration risk; seek speech therapy evaluation
- Sudden confusion or hallucinations — may indicate infection, medication issue, or dementia complication
- Fall with significant injury
Resources
- Parkinson’s Foundation — helpline 1-800-4PD-INFO, clinical guidelines, care centers
- American Parkinson Disease Association (APDA) — local chapters, support groups
- Michael J. Fox Foundation for Parkinson’s Research — research updates, clinical trial matching
- NINDS Parkinson’s Disease Information Page
About this Guide
This Clinical Documentation Guide is published by CCO Academy and is intended for credentialed coding, CDI, and clinical documentation professionals. Content is updated for FY2027 ICD-10-CM (effective October 1, 2026) and CPT/HCPCS 2027 (effective January 1, 2027), with transition notes where CPT 2026 remains applicable through December 31, 2026. All code assignments should be verified against the official ICD-10-CM Tabular List, AHA Coding Clinic, the AMA CPT code set, HCPCS updates, and applicable payer-specific policies. This guide does not constitute legal, medical, or compliance advice.
Last reviewed: April 2026 · Next scheduled review: October 2026 (FY2027 update)
Ready to turn this knowledge into a credential?
These Clinical Documentation Guides are a free companion to CCO’s paid training programs. Browse our full CCO Course, Blitz & Practice Exam Catalog — every core course, review blitz, practice exam, textbook, and free resource in one place — and find the perfect next step for your coding career.
CCO Hero
Know someone starting a medical coding career?
Share your personal CCO link. Your friend saves 20% on their first course or practice exam of $100 or more, and you earn 5% cash on their first enrollment over $100.
Become a CCO Hero